The United Kingdom and the United States have hammered out a major commercial pact that will keep zero import taxes on UK medicine shipments going into the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase funding on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that duties on these crucial exports will be held at nothing for a duration of three years.
This agreement follows earlier threats to hike import taxes on branded drug products, with potential rates mentioned reaching 100%.
"This arrangement with the UK reinforces the worldwide climate for new treatments and introduces long-overdue balance to transatlantic pharmaceutical trade," a release declared.
Commercial Impact
Pharmaceuticals constitute one of the UK's largest exports to the United States, which is by far the largest market for large companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period to the end of last September, the UK sold pharmaceutical products totaling billions to the US. This figure represented 17.4% of total UK exports in that span.
"This agreement secures employment, boosts funding and sets the stage for the UK to become a global hub for medical research," a minister commented.
Specific British Pledges
The deal includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a goal to raise overall public funding on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The percentage drug companies must refund to the NHS to control costs will be restricted at 15%. Previously, repayments topped 20%.
Broader Context
This agreement takes place against a protracted tension between the drug companies and the British authorities over medicine costs and NHS adoption.
The disagreement were exacerbated by claims that US patients were paying a premium for the identical medicines than consumers in the other developed nations.
In recent months, several large drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been announced toward American operations.
A senior figure acknowledged that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a percentage of its resources over the last ten years.
